Avenue Therapeutics

(OTC) ATXI

Current Price$0.32

Market Cap$988.50K

Since IPO (2017)-100%

5 Year-100%

1 Year+39%

1 Month-23%

Avenue Therapeutics Financials at a Glance

Market Cap

$988.50K

Revenue (TTM)

$1.40M

Net Income (TTM)

-$1.75M

EPS (TTM)

-$0.54

P/E Ratio

-0.55

Dividend

$0.00

Beta (Volatility)

0.82 (Low)

Dividend

$0.00

Beta (Volatility)

0.82 (Low)

Price

$0.32

Volume

979

Open

$0.35

Price

$0.32

Volume

979

Open

$0.35

Previous Close

$0.32

Daily Range

$0.32 - $0.35

52-Week Range

$0.15 - $0.97

Estimated Earnings Date

Aug 10, 2026

Dividend

$0.00

Beta (Volatility)

0.82 (Low)

Price

$0.32

Volume

979

Open

$0.35

Previous Close

$0.32

Daily Range

$0.32 - $0.35

52-Week Range

$0.15 - $0.97

Estimated Earnings Date

Aug 10, 2026

ATXI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Avenue Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Alexandra MacLean, MD, MBA

Website

www.avenuetx.com

Headquarters

New York City, NY 10036, US

ATXI Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

-1%

Net Income Margin

-1%

Return on Equity

-74%

Return on Capital

-2%

Return on Assets

-71%

Earnings Yield

-1.82%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$988.50K

Shares Outstanding

3.29M

Volume

979

Avg. Volume

3.95K

Financials (TTM)

Gross Profit

$1.40M

Operating Income

-$3.29M

EBITDA

-$3.29M

Operating Cash Flow

-$1.83M

Capital Expenditure

$0.00

Free Cash Flow

-$1.83M

Cash & ST Invst.

$2.86M

Total Debt

$0.00

Avenue Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$988.50K

N/A

Market Cap/Employee

$494.25K

N/A

Employees

N/A

Net Income

-$695.00K

+62.5%

EBITDA

-$714.00K

+62.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$2.42M

-31.0%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-70.99%

N/A

Return on Invested Capital

-1.75%

N/A

Free Cash Flow

-$438.00K

+63.1%

Operating Cash Flow

-$438.00K

+63.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

DRMADermata Therapeutics, Inc.

DRMADermata Therapeutics, Inc.$1.18-3.28%

VRAXVirax Biolabs Group Limited

VRAXVirax Biolabs Group Limited$0.18+0.88%

WINTWindtree Therapeutics, Inc.

WINTWindtree Therapeutics, Inc.$0.02+28.57%

NCELNewcelX Ltd.

NCELNewcelX Ltd.$3.23-1.11%

CARMCarisma Therapeutics, Inc.

CARMCarisma Therapeutics, Inc.$0.01+7.02%

PBMPsyence Biomedical Ltd.

PBMPsyence Biomedical Ltd.$3.33-4.58%

ELABPMGC Holdings Inc.

ELABPMGC Holdings Inc.$1.47-5.77%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$160.95+0.19%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.59+0.04%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$40.04-0.02%

RKLBRocket Lab

RKLBRocket Lab$102.39-0.11%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.02-0.00%

ONDSOndas

ONDSOndas$9.33-0.05%

ASTSAST SpaceMobile

ASTSAST SpaceMobile$82.41-0.16%

Questions About ATXI

What is the current price of Avenue Therapeutics?

Avenue Therapeutics is trading at $0.32 per share.

What is the 52-week range for Avenue Therapeutics?

Over the past 52 weeks, Avenue Therapeutics has traded between $0.15 and $0.97.

How much debt does Avenue Therapeutics have?

As of the most recent reporting period, Avenue Therapeutics reported total debt of $0.00.

How much cash does Avenue Therapeutics have on hand?

Avenue Therapeutics reported $2.42M in cash and cash equivalents in its most recent financial results.

What is Avenue Therapeutics’s dividend yield?

Avenue Therapeutics does not currently have a dividend yield.

Avenue Therapeutics

Avenue Therapeutics Financials at a Glance

ATXI News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Avenue Therapeutics

ATXI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Avenue Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ATXI

What is the current price of Avenue Therapeutics?

What is the 52-week range for Avenue Therapeutics?

How much debt does Avenue Therapeutics have?

How much cash does Avenue Therapeutics have on hand?

What is Avenue Therapeutics’s dividend yield?

Premium Investing Services